European patch test results with audit allergens as candidates for inclusion in the European Baseline Series, 2019/20: Joint results of the ESSCA(A) and the EBSB working groups of the ESCD, and the GEIDAC(C)
DC Element | Wert | Sprache |
---|---|---|
dc.contributor.author | Uter, Wolfgang | |
dc.contributor.author | Wilkinson, S. Mark | |
dc.contributor.author | Aerts, Olivier | |
dc.contributor.author | Bauer, Andrea | |
dc.contributor.author | Borrego, Leopoldo | |
dc.contributor.author | Buhl, Timo | |
dc.contributor.author | Cooper, Susan M. | |
dc.contributor.author | Dickel, Heinrich | |
dc.contributor.author | Gallo, Rosella | |
dc.contributor.author | Gimenez-Arnau, Ana M. | |
dc.contributor.author | John, Swen M. | |
dc.contributor.author | Navarini, Alexander A. | |
dc.contributor.author | Pesonen, Maria | |
dc.contributor.author | Ponyai, Gyorgyi | |
dc.contributor.author | Rustemeyer, Thomas | |
dc.contributor.author | Schliemann, Sibylle | |
dc.contributor.author | Schubert, Steffen | |
dc.contributor.author | Schuttelaar, Marie-Louise A. | |
dc.contributor.author | Valiukeviciene, Skaidra | |
dc.contributor.author | Wagner, Nicola | |
dc.contributor.author | Weisshaar, Elke | |
dc.contributor.author | Goncalo, Margarida | |
dc.contributor.author | ESSCA Working Grp | |
dc.contributor.author | EBS ESCD Working Grp | |
dc.contributor.author | GEIDAC | |
dc.date.accessioned | 2023-02-17T11:36:57Z | - |
dc.date.available | 2023-02-17T11:36:57Z | - |
dc.date.issued | 2022 | |
dc.identifier.issn | 0105-1873 | |
dc.identifier.uri | http://osnascholar.ub.uni-osnabrueck.de/handle/unios/65648 | - |
dc.description.abstract | Background In 2019, a number of allergens (haptens), henceforth, ``the audit allergens,'' were considered as potential additions to the European Baseline Series (EBS), namely, sodium metabisulfite, 2-bromo-2-nitropropane-1,3-diol, diazolidinyl urea, imidazolidinyl urea, Compositae mix II (2.5% or 5% pet), linalool hydroperoxides (lin-OOH), limonene hydroperoxides (lim-OOH), benzisothiazolinone (BIT), octylisothiazolinone (OIT), decyl glucoside, and lauryl glucoside; Evernia furfuracea (tree moss), was additionally tested by some departments as well. Objectives To collect further data on patch test reactivity and clinical relevance of the audit allergens in consecutive patients across Europe. Methods Patch test data covering the audit allergens in 2019 and 2020 were collected by those departments of the European Surveillance System on Contact Allergies testing these, as well as further collaborators from the EBS working group of the European Society of Contact Dermatitis (ESCD), and the Spanish Grupo Espanol de Investigacion en Dermatitis de Contacto y Alergia Cutanea. As patch test outcome, reactions between day (D) 3 and D5 were considered. Results Altogether n = 12 403 patients were tested with any of the audit allergen. Positive reactions were most common to lin-OOH 1% pet. (8.74% [95%CI: 8.14-9.37%]), followed by lin-OOH 0.5% pet., and lim-OOH 0.3% pet (5.41% [95% CI: 4.95-5.89%]). Beyond these terpene hydroperoxides, BIT 0.1% pet. was the second most common allergen with 4.72% (95% CI: 4.2-5.28%), followed by sodium metabisulfite 1% pet. (3.75% [95%CI: 3.32-4.23%]) and Compositae mix 5% pet. (2.31% [95% CI: 1.84-2.87%]). For some allergens, clinical relevance was frequently difficult to ascertain. Conclusions Despite many positive patch test reactions, it remains controversial whether lin- and lim-OOH should be tested routinely, while at least the two preservatives BIT and sodium metabisulfite appear suitable. The present results are a basis for further discussion and ultimately decision on their implementation into routine testing among the ESCD members. | |
dc.description.sponsorship | EADV Grant [PPRC-2018-8]; Spanish Medicines and Health Products Agency (Agencia Espanola de Medicamentos y Productos Sanitarios); Sanofi; GSK; Novartis; Projekt DEAL; This study was funded in part by the EADV Grant PPRC-2018-8. The EBS working group was funded by EADV Grant PPRC-2018-8. The REIDAC project is promoted by the Fundaci~on Piel Sana Academia Espanola de Dermatologia y Venereologia, which has received financial support from the Spanish Medicines and Health Products Agency (Agencia Espanola de Medicamentos y Productos Sanitarios), and from pharmaceutical companies (Sanofi, GSK, and Novartis).; Open access funding enabled and organized by Projekt DEAL. | |
dc.language.iso | en | |
dc.publisher | WILEY | |
dc.relation.ispartof | CONTACT DERMATITIS | |
dc.subject | Allergy | |
dc.subject | baseline series | |
dc.subject | benzisothiazolinone | |
dc.subject | clinical epidemiology | |
dc.subject | contact allergy | |
dc.subject | CONTACT SENSITIZATION | |
dc.subject | decyl glucoside | |
dc.subject | Dermatology | |
dc.subject | LIMONENE | |
dc.subject | LINALOOL HYDROPEROXIDES | |
dc.subject | MIX | |
dc.subject | patch testing | |
dc.subject | RRID | |
dc.subject | SCR_001905 | |
dc.subject | sodium metabisulfite | |
dc.subject | surveillance | |
dc.title | European patch test results with audit allergens as candidates for inclusion in the European Baseline Series, 2019/20: Joint results of the ESSCA(A) and the EBSB working groups of the ESCD, and the GEIDAC(C) | |
dc.type | journal article | |
dc.identifier.doi | 10.1111/cod.14059 | |
dc.identifier.isi | ISI:000756887100001 | |
dc.description.volume | 86 | |
dc.description.issue | 5 | |
dc.description.startpage | 379 | |
dc.description.endpage | 389 | |
dc.contributor.orcid | 0000-0001-7253-3461 | |
dc.contributor.orcid | 0000-0002-0076-2887 | |
dc.contributor.orcid | 0000-0002-0199-2756 | |
dc.contributor.orcid | 0000-0002-4498-3710 | |
dc.contributor.orcid | 0000-0001-7059-632X | |
dc.contributor.orcid | 0000-0001-7580-0684 | |
dc.contributor.researcherid | AFP-7298-2022 | |
dc.contributor.researcherid | C-5504-2014 | |
dc.identifier.eissn | 1600-0536 | |
dc.publisher.place | 111 RIVER ST, HOBOKEN 07030-5774, NJ USA | |
dcterms.isPartOf.abbreviation | Contact Dermatitis | |
dcterms.oaStatus | Green Published | |
local.import.remains | affiliations : University of Erlangen Nuremberg; University of Leeds; University of Antwerp; University of Antwerp; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Universidad de Las Palmas de Gran Canaria; University of Gottingen; Oxford University Hospitals NHS Foundation Trust; Ruhr University Bochum; University of Genoa; Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; University Osnabruck; University of Basel; Finnish Institute of Occupational Health; Semmelweis University; Friedrich Schiller University of Jena; University of Groningen; Lithuanian University of Health Sciences; University of Erlangen Nuremberg; Ruprecht Karls University Heidelberg; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de Coimbra | |
local.import.remains | earlyaccessdate : FEB 2022 | |
local.import.remains | web-of-science-index : Science Citation Index Expanded (SCI-EXPANDED) | |
crisitem.author.dept | Universität Osnabrück | - |
crisitem.author.orcid | 0000-0001-5406-9458 | - |
crisitem.author.netid | JoSw269 | - |
Seitenaufrufe
1
Letzte Woche
0
0
Letzter Monat
0
0
geprüft am 21.05.2024